Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 50NCT00546377
• PERFORMIndependent statistical analysis of Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma: primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 1,358NCT06372496
• Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 335NCT03966911
• PerformsIndependent statistical analysis of A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01036165).Phase 3Results postedn = 103NCT01036165
• Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04053452).Phase NAResults postedn = 20NCT04053452
• PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 46NCT03581305
• Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 54NCT03257995
• Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 180NCT02968914
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 15NCT04371380
• Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 24NCT03894124
• Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667796).Phase NAResults postedn = 57NCT01667796
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 112NCT01454076
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…Phase 2Results postedn = 9NCT03645395
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 53NCT02145403
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 65NCT01832727
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 32NCT02331368
• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE): Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 56NCT00732940
• Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00530816).Phase 2Results postedn = 164NCT00530816
• Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00369681).Phase 2Results postedn = 51NCT00369681
• Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 38NCT05935332
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…Phase 2Results postedn = 57NCT04140162
• Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 56NCT02991859
• Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 4NCT01743807
• Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 150NCT00506922
• Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…Phase 1Results postedn = 66NCT04134936
• Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).Phase 1/2Results postedn = 4NCT02727777
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 42NCT03236428
• Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 76NCT03005873
• Phase III Cat-PAD Follow-on Study: Complete Statistical AnalysisIndependent statistical analysis of Phase III Cat-PAD Follow-on Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02040844).Phase 3Results postedn = 430NCT02040844
• Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).Phase 1/2Results postedn = 27NCT01251965
• PHM2Independent statistical analysis of Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 33NCT02438189
• PICLSIndependent statistical analysis of Pregnancy Intervention With a Closed-Loop System (PICLS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03774186).Phase NAResults postedn = 24NCT03774186
• Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye: Complete Statistical AnalysisIndependent statistical analysis of Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 64NCT03569202
• Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 12NCT01221857
• Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 6NCT00901303
• Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 10NCT00618371
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 76NCT01338987
• Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02042924).Phase NAResults postedn = 2NCT02042924
• Pinnacle RSA Study: Complete Statistical AnalysisIndependent statistical analysis of Pinnacle RSA Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04070989).Phase NAResults postedn = 100NCT04070989
• Pioglitazone to Treat Fatty Liver in People With HIV Infection: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone to Treat Fatty Liver in People With HIV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00441272).Phase 2Results postedn = 100NCT00441272
• PITCH-EIndependent statistical analysis of Pain Inflammation and Cannabis in HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05554146).Phase NAResults postedn = 35NCT05554146
• Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 60NCT00989664
• PIX-RIndependent statistical analysis of Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are…Phase 3Results postedn = 312NCT01321541
• PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 9NCT05380635
• Placebo In Chronic Back Pain – Double-Blind Randomized Control Trial: Complete Statistical AnalysisIndependent statistical analysis of Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02013427).Phase 4Results postedn = 82NCT02013427
• Plan and Pledge, HIV Self-testing in South Africa: Complete Statistical AnalysisIndependent statistical analysis of Plan and Pledge, HIV Self-testing in South Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03898557).Phase NAResults postedn = 1,479NCT03898557
• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): Complete Statistical AnalysisIndependent statistical analysis of Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 16NCT01518153
• Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye: Complete Statistical AnalysisIndependent statistical analysis of Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 30NCT02257957
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results,…Phase NAResults postedn = 1NCT01076270

← All therapeutic areas